Abstract
Chronic spontaneous urticaria and chronic inducible urticaria are characterized by wheals, angioedema, or both, whereas other conditions such as hereditary angioedema present only with angioedema. The unpredictability of outbreaks, disfigurement, pruritus, and associated sleep and work disturbance can cause a significant impact on quality of life (QoL). Significant breakthroughs in the understanding of these conditions in recent years have led to the development of novel therapies. Assessment of patients with these conditions not only focuses on the clinical activity of the condition, but also on the impact on QoL and disease control with treatment. Patient-reported outcome measures, especially if sufficiently validated, give due prominence to the patient's perspective regarding disease impact and treatment outcomes. This article will review the tools readily available to assess activity, impact, and control in patients with recurrent wheals, angioedema, or both.
| Original language | English |
|---|---|
| Pages (from-to) | 2151-2157 |
| Number of pages | 7 |
| Journal | Journal of Allergy and Clinical Immunology: In Practice |
| Volume | 9 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Jun 2021 |
Bibliographical note
Publisher Copyright:© 2021
Fingerprint
Dive into the research topics of 'How to measure disease activity, impact, and control in patients with recurrent wheals, angioedema, or both'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver